Clinical Scorecard: Six-year LiGHT Data Reviewed at AGS
At a Glance
| Category | Detail |
|---|---|
| Condition | Primary open-angle glaucoma and ocular hypertension |
| Key Mechanisms | Selective laser trabeculoplasty (SLT) lowers intraocular pressure (IOP) and may reduce disease progression and need for surgery |
| Target Population | Treatment-naïve adults newly diagnosed with ocular hypertension or primary open-angle glaucoma without advanced or secondary glaucoma |
| Care Setting | Ophthalmology clinics and glaucoma specialty care |
Key Highlights
- SLT-first treatment achieved comparable visual acuity and visual field preservation to medication-first treatment over 6 years
- Nearly 70% of SLT-first patients maintained drop-free IOP control, with fewer trabeculectomies and cataract surgeries than medication-first patients
- SLT-first approach was more cost-effective with fewer side effects and minimal adverse events reported
Guideline-Based Recommendations
Diagnosis
- Exclude advanced disease, angle-closure, childhood, or secondary glaucoma before initiating treatment
Management
- Use SLT as a first-line treatment with 360° angle treatment and up to two repeat SLT sessions if needed
- Initiate medication therapy per NICE and EGS guidelines if SLT fails or is declined
- Consider repeat SLT after 2 months if initial response is partial or fails
Monitoring & Follow-up
- Set individualized target IOP based on disease severity and adjust according to progression
- Monitor visual acuity and visual field changes regularly to assess disease progression
- Evaluate IOP response at least 2 months post-SLT before considering repeat treatment
Risks
- Minimal adverse events with SLT; 1% experienced IOP rise >5 mmHg
- Medication side effects include periocular pigmentation, lash growth, and ocular discomfort
- Higher risk of cataract surgery and incisional glaucoma surgery in medication-first patients
Patient & Prescribing Data
718 treatment-naïve patients with newly diagnosed ocular hypertension or primary open-angle glaucoma
SLT-first patients had reduced disease progression and fewer surgeries, with 90% controlled after 1 or 2 SLT treatments; medication-first patients had lower mean IOP at 6 years but more progression and surgeries
Clinical Best Practices
- Offer SLT as initial therapy for eligible patients with newly diagnosed open-angle glaucoma or ocular hypertension
- Perform standardized 360° SLT with 100 non-overlapping shots
- Allow up to two repeat SLT treatments before escalating to medical therapy
- Counsel patients on benefits of SLT including reduced medication burden and surgery risk
- Monitor patients closely for IOP control and disease progression to adjust treatment accordingly
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.